What Influences a Woman’s Decision to Stop Chemopreventive Therapy for Breast Cancer? Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Wednesday, January 18, 2017

What Influences a Woman’s Decision to Stop Chemopreventive Therapy for Breast Cancer?



The ASCO Post

 Key Points
  • Worsening of menopause-specific quality of life was associated with early discontinuation of chemopreventive therapy with aromatase inhibitors.
  • Worsening in vasomotor, sexual, physical, and psychosocial domains were each associated with early treatment discontinuation.

Study Details
In the MAP.3 trial, 4,560 high-risk postmenopausal women were randomized between 2004 and 2010 to receive exemestane at 25 mg or placebo for 5 years. The current analysis included 4,501 participants, who completed the Menopause-Specific Quality-of-Life Questionnaire (MENQOL) at study entry and at 6 months.

0 comments :

Post a Comment

Your comments?